key: cord-0857083-sy1wsxtu
authors: Lebourgeois, Samuel; Menidjel, Reyene; Chenane, Houssem Redha; Ferré, Valentine Marie; Collin, Gilles; Damond, Florence; Coppée, Romain; Yazdanpanah, Yazdan; Timsit, Jean-François; Houhou-Fidouh, Nadhira; Descamps, Diane; Charpentier, Charlotte; Visseaux, Benoit
title: Alpha (B.1.1.7) and Delta (B.1.617.2 – AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage
date: 2021-11-19
journal: J Infect
DOI: 10.1016/j.jinf.2021.11.012
sha: 51a05b1bc099de831a151f5c83016b00237158c4
doc_id: 857083
cord_uid: sy1wsxtu

nan

We read with interest the article by Dimeglio et al. 1 Moreover, the infectious capacity of the Delta variant, that could explain in part its epidemiological success, is not characterized. In this study, we investigated the replicative cycle of Delta variant compared to the Alpha and B.1 variants. In addition, we also provided new elements and live virus neutralisation data that strengthen the analysis of vaccinated HCWs antibody responses up to 4 months after the second vaccine dose.

Replication kinetic was performed in triplicates on Vero E6 (ATCC, R CRL-1586) and A549 expressing ACE2 and TMPRSS2 receptors (InvivoGen, a549-hace2tpsa) by analyzing SARS-CoV-2 infectious titers, RNA and N antigen levels. The neutralizing titers of 45 sera from 9

BNT162b2 vaccinated HCWs, up to 5 months after the first vaccine dose, were analyzed by live virus neutralization assays with B.1 (EPI_ISL_4537783), Alpha (EPI_ISL_4536454) and Delta (EPI_ISL_4536228) strains. Decomplemented sera were subjected to serial two-fold dilutions (1:25 to 1:12800), incubated with 50μL of diluted virus at 2×10 3 PFU/mL in a 96well plate at 37°C, 5% CO 2 for 60 min. Then 3x10 4 cells Vero E6 cells were added to each well before being incubated at 37°C, 5% CO 2 .

Lower titers of infectious particles production were observed after 24 hours for strain B.1 (titers comprised on VeroE6 from 2 to 220 PFU/mL for each replicate) than both Alpha and Delta strains (from 4000 to 40000 PFU/mL on VeroE6, p = 0.04) ( fig. 1) . The viral RNA production in culture supernatants were also similar at 24h post-infection for Alpha and Delta variants but approximately 10 times higher than strain B.1 with both cell models (Vero E6: p=0.02; A549: p=0.03). Similar results were obtained with N antigen quantification but as soon as 15 hours after cell infection with similar titers for Alpha and Delta variants and higher than with B.1 (Vero E6: p=0.02; A549: p=0.02). This difference last up to 48 hours (Vero E6: p=0.02; A549: p=0.02) (Fig. 1 ). For all our measurements, a plateau with similar production levels was obtained for all variants since 72 hours.

We also evaluated the level of antibodies neutralization for the Delta strain after full Other important concerns about Delta variant, especially regarding its epidemiological success, are the potential differences on the global viral fitness that has not been characterized to date. Here, we investigated the viral replication kinetics of B.1, Alpha and Delta variants. We evidenced a shorter replication cycle and a quicker production rate of infectious viral particles with both Alpha and Delta strains than with B.1. The 10-times higher in vitro replication levels from 24 to 48 hours post-infection, observed with Alpha and Delta strains, are in line with its higher viral loads and 24h earlier consultation observed among infected patients [8] [9] [10] . The Delta variant, which quickly replaced the Alpha and other variants, presents the same in vitro replication profile than the Alpha strain (Fig. 1) . Thus, if a shorter replication rate could have helped the Alpha strain to successfully emerge over historical variants, and could be a pre-requisite for future variant expansion, other factors must have participated to the emergence of Delta over Alpha. The lower sensitivity to neutralizing antibody is probably a part of this equation.

In conclusion, we highlight a shorter replication cycle and a quicker production of viral materials and infectious particles with Alpha and Delta lineages compared to B.1 lineage. This is expected to play a role and explain in part the higher viral loads, higher transmissibility, and the large epidemiological success of Alpha and Delta variants. We also report a decreased neutralizing titers of BNT162b2 vaccine elicited antibodies against Delta correlated with a decreased sera neutralizing activity four months after complete vaccine scheme in HCWs for all tested strains. These observations highlight the question of vaccine humoral protection lasting and enhance the need for close cellular immunity evaluations against new variants. 1.1.7) , in green and B.1, in red. Viral production has been assessed on two cell lines, Vero E6 and A549, and by RT-qPCR for RNA viral load, plaque assay for infectious particles and ELISA for N antigen production assessment. Results were obtained in triplicates (indicated by dot shapes). A.

The authors have no relevant competing interest to disclose in relation to this work. 

Antibody titers and protection against a SARS-CoV-2 infection

Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine

Waning Immunity after the BNT162b2 Vaccine in Israel

Post-SARS-CoV-2 vaccination specific antibody decrease -Thresholds for determining seroprevalence and seroneutralization differ

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients

This study was supported in part by the ANRS|MIE (Agence Nationale de la Recherche sur le SIDA et les hépatites virales -Maladies Infectieuses Emergentes). We wish to thank Nabil Benmalek for his participation to the current study, as well as all the staff of the virology department for their work on COVID-19, both for patients' care and research support. The authors did not present any conflict of interests with the current work.